Home-based enzyme replacement therapy in children and adults with Pompe disease; a prospective study

Home-based enzyme replacement therapy in children and adults with Pompe disease; a prospective study

Abstract Background Pompe disease is a lysosomal storage disease treated with life-long enzyme replacement therapy (ERT). Home-based ERT has been provided in the Netherlands since 2008 because it diminishes the burden of treatment, increases patient flexibility and autonomy, and is thus a more patie...

Full description

Bibliographic Details
Main Authors:	Imke A. M. Ditters, Nadine A. M. E. van der Beek, Esther Brusse, Ans T. van der Ploeg, Johanna M. P. van den Hout, Hidde H. Huidekoper
Format:	Article
Language:	English
Published:	BMC 2023-05-01
Series:	Orphanet Journal of Rare Diseases
Subjects:	Pompe disease Glycogen storage disease type II Enzyme replacement therapy (ERT) Alglucosidase alfa Home treatment Infusion associated reactions (IARs)
Online Access:	https://doi.org/10.1186/s13023-023-02715-4

Similar Items

Higher dose alglucosidase alfa is associated with improved overall survival in infantile-onset Pompe disease (IOPD): data from the Pompe Registry
by: Priya S. Kishnani, et al.
Published: (2023-12-01)

Benefit of 5 years of enzyme replacement therapy in advanced late onset Pompe. A case report of misdiagnosis for three decades with acute respiratory failure at presentation
by: Mandat Maharaj, et al.
Published: (2022-09-01)

Efficacy and safety of enzyme replacement therapy with alglucosidase alfa for the treatment of patients with infantile-onset Pompe disease: a systematic review and metanalysis
by: A. D. Dornelles, et al.
Published: (2024-02-01)

Optimizing treatment outcomes: immune tolerance induction in Pompe disease patients undergoing enzyme replacement therapy
by: Hui-An Chen, et al.
Published: (2024-04-01)

Enzyme replacement therapy reduces the risk for wheelchair dependency in adult Pompe patients
by: Jan C. van der Meijden, et al.
Published: (2018-05-01)

Effect of enzyme therapy and prognostic factors in 69 adults with Pompe disease: an open-label single-center study
by: de Vries Juna M, et al.
Published: (2012-09-01)

A Multi-Centre Prospective Study of the Efficacy and Safety of Alglucosidase Alfa in Chinese Patients With Infantile-Onset Pompe Disease
by: Diqi Zhu, et al.
Published: (2022-06-01)

Real-world outcomes from a series of patients with late onset Pompe disease who switched from alglucosidase alfa to avalglucosidase alfa
by: Chris Carter, et al.
Published: (2024-01-01)

Distal muscle weakness is a common and early feature in long-term enzyme-treated classic infantile Pompe patients
by: J. J. A. van den Dorpel, et al.
Published: (2020-09-01)

Are Anti-rhGAA Antibodies a Determinant of Treatment Outcome in Adults with Late-Onset Pompe Disease? A Systematic Review
by: Imke A. M. Ditters, et al.
Published: (2023-09-01)

Clinical and molecular characterization of Korean children with infantile and late-onset Pompe disease: 10 years of experience with enzyme replacement therapy at a single center
by: Min-Sun Kim, et al.
Published: (2019-06-01)

Late-onset Pompe disease - literature review and summary of current knowledge
by: Karolina Jaskuła, et al.
Published: (2023-01-01)

Long term clinical history of an Italian cohort of infantile onset Pompe disease treated with enzyme replacement therapy
by: Rossella Parini, et al.
Published: (2018-02-01)

Long-Term Observation of the Safety and Effectiveness of Enzyme Replacement Therapy in Japanese Patients with Pompe Disease: Results From the Post-marketing Surveillance
by: Hitoshi Nagura, et al.
Published: (2019-09-01)

The Clinical Management of Pompe Disease: A Pediatric Perspective
by: Jorge Sales Marques
Published: (2022-09-01)

Antibodies against recombinant human alpha-glucosidase do not seem to affect clinical outcome in childhood onset Pompe disease
by: Harmke A. van Kooten, et al.
Published: (2022-02-01)

Improved Enzyme Replacement Therapy with Cipaglucosidase Alfa/Miglustat in Infantile Pompe Disease
by: Lina Fiege, et al.
Published: (2023-08-01)

Enzyme replacement therapy and antibodies in late-onset Pompe disease
by: I. Schneider, et al.
Published: (2014-01-01)

Effects of immunomodulation in classic infantile Pompe patients with high antibody titers
by: E. Poelman, et al.
Published: (2019-03-01)

IGF2-tagging of GAA promotes full correction of murine Pompe disease at a clinically relevant dosage of lentiviral gene therapy
by: Qiushi Liang, et al.
Published: (2022-12-01)

An updated management approach of Pompe disease patients with high-sustained anti-rhGAA IgG antibody titers: experience with bortezomib-based immunomodulation
by: Ankit K. Desai, et al.
Published: (2024-03-01)

Multicentric Retrospective Evaluation of Five Classic Infantile Pompe Disease Subjects Under Enzyme Replacement Therapy With Early Infratentorial Involvement
by: Matteo Paoletti, et al.
Published: (2020-11-01)

Novel GAA Variants and Mosaicism in Pompe Disease Identified by Extended Analyses of Patients with an Incomplete DNA Diagnosis
by: Stijn L.M. in ’t Groen, et al.
Published: (2020-06-01)

Chest MRI to diagnose early diaphragmatic weakness in Pompe disease
by: Laurike Harlaar, et al.
Published: (2021-01-01)

Cost-effectiveness of enzyme replacement therapy with alglucosidase alfa in adult patients with Pompe disease
by: Tim A. Kanters, et al.
Published: (2017-12-01)

A Systematic Review and Meta-Analysis of Enzyme Replacement Therapy in Late-Onset Pompe Disease
by: Alícia Dorneles Dornelles, et al.
Published: (2021-10-01)

Pregnancy Outcomes in Late Onset Pompe Disease
by: Ozlem Goker-Alpan, et al.
Published: (2020-09-01)

Treatment Dilemma in Children with Late-Onset Pompe Disease
by: Martha Caterina Faraguna, et al.
Published: (2023-01-01)

Moss-Derived Human Recombinant GAA Provides an Optimized Enzyme Uptake in Differentiated Human Muscle Cells of Pompe Disease
by: Stefan Hintze, et al.
Published: (2020-04-01)

Reporting 7 Pompe Patients in Iran
by: Milad Ebrahimi, et al.
Published: (2017-05-01)

A study on the safety and efficacy of reveglucosidase alfa in patients with late-onset Pompe disease
by: Barry J. Byrne, et al.
Published: (2017-08-01)

Homozygotic intronic GAA mutation in three siblings with late-onset Pompe's disease Mutação homozigótica intrônica no gene GAA em três irmãos com doença de Pompe de início tardio
by: Anderson Kuntz Grzesiuk, et al.
Published: (2010-04-01)

Skeletal muscle metabolism during prolonged exercise in Pompe disease
by: Nicolai Preisler, et al.
Published: (2017-07-01)

Characteristics of Pompe disease in China: a report from the Pompe registry
by: Yuying Zhao, et al.
Published: (2019-04-01)

Late-Onset Pompe Disease Presenting with Isolated Tongue Involvement
by: Jasem Al-Hashel, et al.
Published: (2022-03-01)

Pompe Disease: Early Diagnosis and Early Treatment Make a Difference
by: Yin-Hsiu Chien, et al.
Published: (2013-08-01)

Hypothyroidism in late-onset Pompe disease
by: Joseph Schneider, et al.
Published: (2016-09-01)

Calf muscle hypertrophy in late onset pompe's disease
by: M Suraj Menon, et al.
Published: (2016-01-01)

Current pharmacotherapy and diagnostic methods of Pompe Disease in Poland
by: Dominika Anna Janeczko, et al.
Published: (2019-09-01)

Current pharmacotherapy and diagnostic methods of Pompe Disease in Poland
by: Dominika Anna Janeczko, et al.
Published: (2019-09-01)